イオニスの経営陣は 強い利益と収益の成長の中で 株を売り切った 株価は73.65ドル近くだった Ionis execs sold shares amid strong earnings and revenue growth, with stock near $73.65.

イオニス製薬 (IONS) のジョセフ・ウェンダー取締役は10月31日に11,200株をそれぞれ75.16ドルで売却し,その持分を14.89%減らし,約481万ドルの価値の64,035株にしました. Ionis Pharmaceuticals (IONS) Director Joseph Wender sold 11,200 shares on October 31 at $75.16 each, reducing his stake by 14.89% to 64,035 shares valued at about $4.81 million. リチャード・ゲーリー副社長も同日に89万249株を販売し,その所有権を約60パーセント削減した. Executive Vice President Richard Geary also sold 89,249 shares on the same day, cutting his ownership by nearly 60%. 株価は月曜日に73.65ドルで閉店し,0.65ドル下落し,取引量が増加した. The stock closed at $73.65 on Monday, down $0.65, with elevated trading volume. イオニスは,第3四半期に1株当たり0.80ドルで,推定値を0.35ドル上回り,売上高は前年比17.2%増加して157百万ドルとなった. Ionis reported third-quarter earnings of $0.80 per share, beating estimates by $0.35, and revenue rose 17.2% year-over-year to $157 million. 会社の市場資本は193億円で,マイナスのP/E比は-43.58ドルです. The company has a market cap of $11.93 billion and a negative P/E ratio of -43.58. 分析者は83.05ドルの目標で"適度な購入"のコンセンサス評価を維持しており,いくつかの企業は,SPINRAZA,TEGSEDI,WAYLIVRAのようなRNA標的治療における成長可能性を挙げて,目標値を引き上げました. Analysts maintain a "Moderate Buy" consensus rating with a target of $83.05, and several firms raised their targets, citing growth potential in its RNA-targeted therapies like SPINRAZA, TEGSEDI, and WAYLIVRA.